Acadia Pharmaceuticals has decided to halt trials of its antipsychotic drug after it failed a study on schizophrenia. The drug, Nuplazid, did not show improvement in social and emotional symptoms of schizophrenia in a late-stage clinical trial, impacting the company's expansion plans.
Acadia Pharmaceuticals said its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage trial. https://t.co/I41lkLVLJV
Acadia Pharmaceuticals' approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial. https://t.co/fkYv0l7gqR
Acadia drug fails schizophrenia trial, setting back company’s expansion plans https://t.co/TqbWofPXZv $ACAD By Kristin Jensen
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more news.. https://t.co/WblxOJRbAh #pharma #RSV #vaccines #Medicaid #patents #opioids #cancer #schizophrenia $PFE $WMT $ACAD $GSK $AZN $VTRS $FSNUY
$ACAD (-16.0% pre) Acadia to stop trials of antipsychotic drug after it fails schizophrenia study https://t.co/rm53ZSxCO0
Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study https://t.co/X7JrLSD4K3 https://t.co/ddYP770Q8f